Optimal Duration of Neoadjuvant Gemcitabine + Cisplatin for MIBC Probed
The neoadjuvant chemotherapy regimen may be especially effective against micrometastatic disease, investigators suggested.
The neoadjuvant chemotherapy regimen may be especially effective against micrometastatic disease, investigators suggested.
The proportion of excess cancer risk in men that was explained by risk factors was modest, ranging from 50 to 11%
Pain requiring opioids is more common among patients with locally advanced or metastatic urothelial carcinoma compared with a matched control group of patients without cancer, a study found.
For patients treated with adequate BCG, risk for BCG unresponsiveness, progression similar for all high-grade Ta tumors
Investigators studied the effect of sequential valrubicin and docetaxel in patients with recurrent NMIBC following treatment with intravesical bacillus Calmette-Guérin and/or gemcitabine-docetaxel.
Although the risks of developing a second primary cancer after radiation therapy were relatively small, they increased over time.
Adding olaparib to durvalumab did not improve progression-free or overall survival.
A propensity-score matched comparison revealed no significant difference in oncologic outcomes between radical cystectomy and trimodal therapy.
Anemia can identify patients at higher risk for radical cystectomy complications and may be useful in preoperative counseling, according to investigators.
Among patients receiving radiation therapy (RT) for prostate cancer, intensity-modulated radiation therapy is significantly associated with a reduced risk for second primary solid malignancies compared with 3D conformal RT.